Patent Owners Struck With “Sticker Shock” At PTO’s Proposed Fees
The Patent and Trademark Office issued a proposed fee schedule as part of its implementation of the Leahy-Smith America Invents Act; post-grant review fees could deter use of the procedure, Lilly’s general counsel says.
You may also be interested in...
President Obama announce seven initiatives to help move ideas from the lab to market as he signs the Leahy-Smith America Invents Act.
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
The agency's "Bad Ad" program issued a warning letter that claims the promotion for CooperSurgical's copper-containing intrauterine contraceptive lacked any safety information.